Underwhelming.
That single word may best describe the market reception for the second New York IPO in more than half a year by a Chinese company, as the China-U.S. listing pipeline slowly returns to life. The muted market reception isn’t too surprising, since the listing has come from a relatively low tech disposable medical device maker called Meihua International Medical Technologies Co. Ltd. (MHUA.US).
Nearly everything about this particular listing says “ho-hum,” and the reality is that few people would have noticed it at this time last year. But it’s drawing unusual attention now as only the second Chinese company to make it to market since last summer, when such IPOs ground to a halt after both Beijing and Washington expressed different sets of concerns. The other IPO came from a drug startup called LianBio (LIAN.US), which raised $325 million from its listing last November.